BLSM vs RLMD: stock comparison and AI forecast
Blossomhill Therapeutics, Inc. (BLSM) and Relmada Therapeutics, Inc. (RLMD) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
BLSM Blossomhill Therapeutics, Inc.
- Market Cap
- $395M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
RLMD Relmada Therapeutics, Inc.
- Market Cap
- $410M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- BLSM and RLMD have similar market capitalizations ($395M and $410M).
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | BLSM | RLMD |
|---|---|---|
| Market Cap | $395M | $410M |
| P/B Ratio | – | 1.98x |
| EPS | – | $-1.26 |
| Book Value/Share | – | $1.94 |
Profitability & Margins
| Metric | BLSM | RLMD |
|---|---|---|
| ROIC | – | -30.8% |
Financial Health
| Metric | BLSM | RLMD |
|---|---|---|
| Current Ratio | 5.42x | 29.52x |
| D/E Ratio | – | 0.06x |
| Financial Leverage | – | 1.06x |
| Interest Coverage | – | -21.3x |
| Working Capital | $82M | $212M |
Cash Flow
| Metric | BLSM | RLMD |
|---|---|---|
| Operating Cash Flow | – | -$46M |
Income Statement
| Metric | BLSM | RLMD |
|---|---|---|
| Operating Income | – | -$65M |
| R&D Expense | – | $29M |
Dividend & Shareholder Information
| Metric | BLSM | RLMD |
|---|---|---|
| Shares Outstanding | 32M | 107M |
BLSM vs RLMD: stock comparison and AI forecast
Which is bigger, BLSM or RLMD?
BLSM and RLMD have similar market capitalizations ($395M and $410M).
Which one does Intratio's AI model rank higher, BLSM or RLMD?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.